| Small Lymphocytic Lymphoma
Venclexta vs Brukinsa
Side-by-side clinical, coverage, and cost comparison for small lymphocytic lymphoma.Deep comparison between: Venclexta vs Brukinsa with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsBrukinsa has a higher rate of injection site reactions vs Venclexta based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Brukinsa but not Venclexta, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Venclexta
Brukinsa
At A Glance
Oral
Once daily
BCL-2 inhibitor
Oral
Once or twice daily
BTK inhibitor
Indications
- Chronic Lymphocytic Leukemia
- Small Lymphocytic Lymphoma
- Leukemia, Myelocytic, Acute
- Mantle cell lymphoma
- Waldenstrom Macroglobulinemia
- Marginal Zone B-Cell Lymphoma
- Chronic Lymphocytic Leukemia
- Small Lymphocytic Lymphoma
- Lymphoma, Follicular
Dosing
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma 5-week ramp-up starting at 20 mg, increasing to 400 mg orally once daily; used as monotherapy or in combination with acalabrutinib, obinutuzumab, or rituximab.
Leukemia, Myelocytic, Acute 3- or 4-day ramp-up to 400 mg orally once daily in combination with azacitidine or decitabine, or 600 mg orally once daily in combination with low-dose cytarabine, each in 28-day cycles.
Mantle cell lymphoma, Waldenstrom Macroglobulinemia, Marginal Zone B-Cell Lymphoma, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma 160 mg orally twice daily or 320 mg orally once daily, with or without food, until disease progression or unacceptable toxicity.
Lymphoma, Follicular 160 mg orally twice daily in combination with obinutuzumab, with or without food, until disease progression or unacceptable toxicity.
Contraindications
- Concomitant use with strong CYP3A inhibitors at initiation and during the ramp-up phase in patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma due to increased risk of tumor lysis syndrome
—
Adverse Reactions
Most common (>=20%) in CLL/SLL Neutropenia, thrombocytopenia, anemia, diarrhea, nausea, upper respiratory tract infection, cough, musculoskeletal pain, fatigue, edema
Most common (>=30%) in AML Nausea, diarrhea, thrombocytopenia, constipation, neutropenia, febrile neutropenia, fatigue, vomiting, edema, pyrexia, pneumonia, dyspnea, hemorrhage, anemia, rash, abdominal pain, sepsis, musculoskeletal pain, dizziness, cough, oropharyngeal pain, hypotension
Serious Tumor lysis syndrome, febrile neutropenia, pneumonia, sepsis, hemorrhage
Most common (>=30%) Neutrophil count decreased, platelet count decreased, upper respiratory tract infection, hemorrhage, musculoskeletal pain
Serious Hemorrhage, pneumonia, cytopenias, second primary malignancies, cardiac arrhythmias, hepatotoxicity including drug-induced liver injury
Postmarketing Drug-induced liver injury
Pharmacology
BCL-2 inhibitor; venetoclax is a selective, orally bioavailable small-molecule that restores apoptosis by binding directly to the BCL-2 protein, displacing pro-apoptotic proteins like BIM and triggering mitochondrial outer membrane permeabilization and activation of caspases.
Zanubrutinib is a small-molecule inhibitor of Bruton's tyrosine kinase (BTK) that forms a covalent bond with a cysteine residue in the BTK active site, inhibiting BTK activity and thereby blocking B-cell proliferation, trafficking, chemotaxis, and adhesion pathways driven by B-cell antigen receptor and cytokine receptor signaling.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Venclexta
- Covered on 5 commercial plans
- PA (11/12) · Step Therapy (9/12) · Qty limit (11/12)
Brukinsa
- Covered on 5 commercial plans
- PA (12/12) · Step Therapy (0/12) · Qty limit (11/12)
UnitedHealthcare
Venclexta
- Covered on 4 commercial plans
- PA (8/8) · Step Therapy (0/8) · Qty limit (8/8)
Brukinsa
- Covered on 4 commercial plans
- PA (5/8) · Step Therapy (5/8) · Qty limit (4/8)
Humana
Venclexta
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
Brukinsa
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (0/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Venclexta.
No savings programs available for Brukinsa.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
VenclextaView full Venclexta profile
BrukinsaView full Brukinsa profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.